ESR1 and breast carcinoma: The over expression of ER-α and Her-2/neu are biomarkers for aggressive types of breast cancer as activation of either receptor stimulates proliferatory pathways by increasing DNA replication, which increases the possibility of cancer-causing mutations [22,23].